Literature DB >> 11797649

Chemical pleurodesis for hepatic hydrothorax.

I F Boin1, A M Silva, L S Leonardi.   

Abstract

BACKGROUND: Ascites can occur after hepatic diseases causing dyspnea, coughing and pain. When associated with pleural effusion it can also increase respiratory distress. In a bibliographic survey hydrothorax has been observed in up to 20% of the patients and the kind of treatment is still being discussed.
OBJECTIVE: This case report shows the occurrence of a large volume of ascites and pleural effusion in a cirrhotic patient and his treatment.
METHODS: Report the case of a patient with hepatic cirrhosis due to chronic alcoholism and massive pleural effusion and ascites. He was submitted to several pleural paracenteses without success. Scintigraphy showed the presence of ascites and confirmed a possible pleuroperitoneal communication. The thoracic surgery group was called and after evaluation it was decided to submit the patient to a pulmonary decortication and chemical pleurodesis.
RESULTS: These procedures were carried out with success. The pleural effusion was solved and the treatment of ascites was decided upon because the patient did not accept any surgical procedure.
CONCLUSION: This treatment could be applied to patients with hydrothorax who could not be submitted to a liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11797649     DOI: 10.1590/s0004-28032001000200008

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  2 in total

Review 1.  Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis.

Authors:  Feifei Hou; Xingshun Qi; Xiaozhong Guo
Journal:  Dig Dis Sci       Date:  2016-07-25       Impact factor: 3.199

2.  Success of Using Iodopovidone as a Sclerosing Agent for Chemical Pleurodesis in a Tertiary Care Center: A Descriptive Cross-Sectional Study.

Authors:  Deebya Raj Mishra; Narendra Bhatta; Puru Koirala; Bhupendra Shah; Bidesh Bista; Niharika Shah
Journal:  JNMA J Nepal Med Assoc       Date:  2021-01-31       Impact factor: 0.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.